Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo

European Journal of Neuroscience

Volumn 12, Issue 10, 2000, Pages 3721-3728

  Do, K Q ^a,b   Trabesinger, A H ^a,b,c   Kirsten Kruger M ^a,b,d   Lauer, C J ^a,b,e   Dydak, U ^a,b,c   Hell, D ^a,b,d   Holsboer, F ^a,b,e   Boesiger, P ^a,b,c   Cuenod M ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^e MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Dopamine; Glutamate; Human; Magnetic resonance spectroscopy; Oxidative stress

Indexed keywords

DOPAMINE; GLUTAMINE DERIVATIVE; GLUTATHIONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROPROTECTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; GLUTATHIONE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; NERVE DEGENERATION; PREFRONTAL CORTEX; PRESYNAPTIC TERMINALS; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA;

EID: 0033787297     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2000.00229.x     Document Type: Article

References (56)

1. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients
2. Hypofrontality in neuroleptic-naive patients and in patients with schizophrenia
3. Glutathione transferases catalyse the detoxication of oxidized
4. Separation of the different orders of NMR multiple-quantum transitions by the use of pulsed field gradients
5. Evidence for neurodevelopment disturbances in anterior cingulate cortex of post-mortem schizophrenic brain
6. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia
7. Advancing a neurodevelopmental origin for schizophrenia
8. Spatial localization in NMR spectroscopy in vivo
9. Glutathione peroxidase and CT scan abnormalities in schizophrenia
10. The current status of the dopamine hypothesis of schizophrenia
11. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
12. Catalase, glutathione peroxidase, superoxide dismutase and cytochrome P-450
13. Glutathione in the brain: Disorders of glutathione metabolism
14. Dopamine in schizophrenia: A review and reconceptualization
15. A 'glutamatergic hypothesis' of schizophrenia
16. Gamma-glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders
17. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGly as precursor for neuronal glutathione
18. Quantitative 1H MRS of the human brain in vivo based on the simulation phantom calibration strategy
19. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia
20. Specificity of decreased spine density on layer III pyramidal cells in schizophrenia
21. Working memory dysfunction in schizophrenia
22. Dopamine synaptic complex with pyramidal neurons in primate cerebral cortex
23. Autoxidation versus covalent binding of quinones as the mechanism of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro
24. The neuropathology of schizophrenia. A critical review of the data and their interpretation
25. Recent advances in the phencyclidine model of schizophrenia
26. Glutathione and signal transduction in the mammalian CNS
27. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia
28. NMDA receptor channels: Subunit-specific potentiation by reducing agents
29. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy
30. Quantitative three-dimensional analysis of the catecholaminergic innervation of identified neurons in the macaque prefrontal cortex
31. Free radical pathology and antioxidant defense in schizophrenia - A review
32. Elevated plasma lipid peroxides at the onset of nonaffective psychosis
33. Antipsychotic drug actions: A clue to the neuropathology of schizophrenia?
34. Glutathione
35. Impaired antioxidant defense at the onset of psychosis
36. Is schizophrenia a neurodevelopmental disorder?
37. Prevention of dopamine-induced cell death by thiol antioxidants
38. Decreased prefrontal dopamine d1 receptors in schizophrenia revealed by pet
39. Glutamate receptor dysfunction and schizophrenia
40. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
41. High-affinity zinc inhibition of NMDA NR1-NR2A receptors
42. Schizophrenic trait features, binding, and cortico-cortical connectivity: A neurodevelopmental pathogenetic hypothesis
43. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy
44. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics
45. Role of endogenous glutathione in the oxidation of dopamine
46. Free radical pathology in schizophrenia: A review
47. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17
48. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method
49. Psychomotor effects of dopamine infusion under decreased glutathione
50. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease
51. Identification of two cysteine residues that are required for redox modulation of the NMDA subtype of glutamate receptor
52. Interaction of gamma-glutamyl transpeptidase with amino acids, dipeptides, and derivatives and analogs of glutathione
53. Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering
54. Implications of normal brain development for the pathogenesis of schizophrenia
55. Human plasma glutathione peroxidase and symptom severity in schizophrenia
56. Screening of thiol compounds: Depolarization-induced release of glutathione and cysteine from rat brain slices